Home LiteratureArticle Details
PMID: 10992004 Published · ppublish English Journal Article

Nonpeptide tachykinin receptor antagonists. II. Pharmacological and pharmacokinetic profile of SB-222200, a central nervous system penetrant, potent and selective NK-3 receptor antagonist.

The Journal of pharmacology and experimental therapeutics ·Vol. 295 ·No. 1 ·2000-10-00 ·Pages 373-81

Sarau HM, Griswold DE, Bush B, Potts W, Sandhu P, Lundberg D, Foley JJ, Schmidt DB, Webb EF, Martin LD, Legos JJ, Whitmore RG, Barone FC, Medhurst AD, Luttmann MA, Giardina GA, Hay DW

Abstract

The pharmacological and pharmacokinetic profile of SB-222200 [(S)-(-)-N-(alpha-ethylbenzyl)-3-methyl-2-phenylquinoline-4-car boxami de], a human NK-3 receptor (hNK-3R) antagonist, was determined. SB-222200 inhibited (125)I-[MePhe(7)]neurokinin B (NKB) binding to Chinese hamster ovary (CHO) cell membranes stably expressing the hNK-3 receptor (CHO-hNK-3R) with a K(i) = 4.4 nM and antagonized NKB-induced Ca(2+) mobilization in HEK 293 cells stably expressing the hNK-3 receptor (HEK 293-hNK-3R) with an IC(50) = 18.4 nM. SB-222200 was selective for hNK-3 receptors compared with hNK-1 (K(i) > 100,000 nM) and hNK-2 receptors (K(i) = 250 nM). In HEK 293 cells transiently expressing murine NK-3 receptors (HEK 293-mNK-3R), SB-222200 inhibited binding of (125)I-[MePhe(7)]NKB (K(i) = 174 nM) and antagonized NKB (1 nM)-induced calcium mobilization (IC(50) = 265 nM). In mice oral administration of SB-222200 produced dose-dependent inhibition of behavioral responses induced by i.p. or intracerebral ventricular administration of the NK-3 receptor-selective agonist, senktide, with ED(50) values of approximately 5 mg/kg. SB-222200 effectively crossed the blood-brain barrier in the mouse and rat. The inhibitory effect of SB-222200 against senktide-induced behavioral responses in the mouse correlated significantly with brain, but not plasma, concentrations of the compound. Pharmacokinetic evaluation of SB-222200 in rat after oral administration (8 mg/kg) indicated sustained plasma concentrations (C(max) = about 400 ng/ml) and bioavailability of 46%. The preclinical profile of SB-222200, demonstrating high affinity, selectivity, reversibility, oral activity, and central nervous system penetration, suggests that it will be a useful tool compound to define the physiological and pathophysiological roles of NK-3 receptors, in particular in the central nervous system.

MeSH Terms
Animals Brain/drug effects,metabolism CHO Cells Calcium/metabolism Cricetinae Dose-Response Relationship, Drug Humans In Vitro Techniques Iris/drug effects,physiology Male Mice Mice, Inbred BALB C Peptide Fragments/pharmacology Quinolines/pharmacokinetics,pharmacology Rabbits Rats Rats, Sprague-Dawley Receptors, Neurokinin-3/antagonists & inhibitors Substance P/analogs & derivatives,pharmacology
Chemicals
Peptide Fragments Quinolines Receptors, Neurokinin-3 SB 222200 senktide Substance P Calcium
Authors & Affiliations
17 authors, click to expand affiliations / ORCID
Sarau H M
The Departments of Pulmonary Biology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania, USA.
Griswold D E
Bush B
Potts W
Sandhu P
Lundberg D
Foley J J
Schmidt D B
Webb E F
Martin L D
Legos J J
Whitmore R G
Barone F C
Medhurst A D
Luttmann M A
Giardina G A
Hay D W
Article Info
Journal
The Journal of pharmacology and experimental therapeutics
Abbr.
J Pharmacol Exp Ther
ISSN
0022-3565
Published
2000-10-00
Pages
373-81
Language
English
Region
United States
NLM ID
0376362
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]